RxDoctor Payments Data

Karsyn Lovretin, PA

Medical · Melbourne, FLNPI 1710588363

Payments from drug & device makers

$896in general payments, 2019–2025

Across 30 payments — averaging $29.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$422
  • E.r. Squibb & Sons, L.L.C.$160
  • Medtronic$132
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$79
  • Abbott$38
  • Novartis$31
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$86596%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$896 in reported general payments places this provider in the 55th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$171,416
Medicare patients
666
Services billed
2,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$157,191
MultaqDronedarone Hcl45$65,605
XareltoRivaroxaban47$52,626
Dabigatran EtexilateDabigatran Etexilate Mesylate27$5,822
Metoprolol Succinate145$3,213
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,162
Amiodarone Hcl67$2,125
Flecainide Acetate60$1,999
Midodrine Hcl14$859
Digoxin25$856
SotalolSotalol Hcl33$846
Propafenone Hcl13$628
Losartan Potassium56$614
Carvedilol45$472
Propranolol Hcl16$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$21$52,62647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,031 medical providers in Florida.

Other medical in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →